The 23andMe deal with GlaxoSmithKline raises privacy and ethics questions
The pharmaceutical giant GlaxoSmithKline announced a move late last month to invest $300 million in the genetic testing company 23andMe, in addition to a deal giving exclusive access to its collection of geneti...